Clinical Trial

A Phase 3 Trial of DT120 for Generalized Anxiety Disorder (Voyage)

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated June 22, 2026 (before its estimated July 2026 completion). Its status may not reflect the trial's current state.
Summary
A Phase 3 Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating DT120 Compared to Placebo in Generalized Anxiety Disorder - Voyage
Protocol Amendment History 2 changes
notable Primary completion pushed: 2026-05 -> 2026-07 2026-06-23
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-05-02
Trial Details
NCT Number NCT06741228
Lead Sponsor Definium Therapeutics US, Inc.
Conditions Generalized Anxiety Disorder
Enrollment 214 participants
Start Date 2024-12-11
Primary Completion 2026-07 (estimated)
Study Completion 2026-11 (estimated)
Updated on ClinicalTrials.gov 2026-06-22